The synergistic effect of olefin and gefitinib on NSCLC cells depends in part on the downregulation of EZH2, an H3K27 methyltransferase recognized as a gene transcription regulator and cancer driver primarily through its epigenetic and global ability to modify tumor-related genes [78,79]. This evidence concerns the gene EZH2 and neoplasm.